Evidentiq and Dacima Software of Canada join forces to offer end-to-end software for clinical trials

EvidentIQ, 15 Jun 2022

EvidentIQ, a pioneering provider of end-to-end eClinical solutions, and Dacima Software Inc. of Montréal, a leading provider of data management software solutions for clinical trials, have signed an agreement that will result in the acquisition of Dacima.

Through its advanced eClinical solution “DACIMA Clinical Suite”, the Canadian software company offers a flexible platform for the design and management of clinical trials, patient registries, observational studies and clinical databases. EvidentIQ‘s market leading Real-Word Evidence (RWE) and Decentralized Clinical Trials (DCT) capabilities will be further enriched by Dacima‘s cutting edge eClinical technology assets, such as electronic Patient Reported Outcome reporting (ePRO), electronic Clinical Outcome Assessment (eCOA), eDiary and eConsent. With these additions, the EvidentIQ Group will be able to cover the entire value chain in clinical development, from trial planning over phase 1-3 to market access and post marketing observational studies. So the group will provide the technology for hybrid and decentralized clinical trials (DCT) as a one-stop-shop on a global basis.

EvidentIQ Group combines end-to-end eClinical solutions with a broad data science service portfolio and patient recruitment capabilities. Pharmaceutical and medical device companies, clinical research institutions and universities worldwide rely on the group’s products. In addition to its current locations in Germany, France and the USA, EvidentIQ is now strengthening its North American focus with the envisaged acquisition of Canada-based Dacima. The transaction is expected to close by the end of June 2022.


Cloud Migration: This is what the move to the cloud means for your company - and the IT team!


UntermStrich software and KOBOLD Management Systeme join forces in the future

More EvidentIQ news

12 Sep 2019

BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies.

25 Jan 2021

BID Equity Fund II, a fund advised by BID Equity, acquires France-based Carenity, an anlytics platform supporting +500,000 patients and caregivers worldwide.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system.